News Archive
Debiopharm Group, a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Ascepion Pharmaceuticals, Inc., a privately-held, biopharmaceutical company dedicated to the discovery and development of breakthrough small molecule drugs for the treatment of oncology and related diseases, have entered into an exclusive worldwide license agreement concerning the development and commercialization of ASP-08126 (called Debio 1144 by Debiopharm) a multikinase inhibitor currently in pre-clinical development.
Giving supplement such as herbs, vitamins, and other natural health products to children taking Warfarin for congenital heart defects could increase their risk of clots, bleeding, and other complications, nurse practitioner Mary Bauman and Dr. Patti Massicotte told the 2008 Canadian Cardiovascular Congress, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.
A shorter life may be the price an organism pays for coping with the natural assaults of daily living, according to researchers at the National Institutes of Health and their colleagues in Japan.
People who work night shifts are at increased risk of developing an irregular and often abnormally fast heart rhythm called atrial fibrillation (AF), according to research published in the European Heart Journal.
The Associated Press reports that some of the newly insured will now become the faces of healthcare.gov, while The New York Times tells three stories about people who won't be able to keep their coverage.
› Verified 1 days ago